- The P-III program consists of two trials (ISABELA 1 & 2) assessing ziritaxesta (200/ 600mg, qd) + SOC vs PBO + SOC in ~1500 patients with IPF. The 1EPs of the study decline in forced vital capacity until 52wks.
- The termination of the study is based IDMC’s recommendation following a regular review of unblinded data, which concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies
- Ziritaxestat is an investigational autotaxin inhibitor. Additionally, all clinical trials with ziritaxestat includes the long-term extension of P-IIa NOVESA trial in systemic sclerosis will be discontinued
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Made in